Orlando Guntinas-Lichius1, Thomas G Wendt2, Nicole Kornetzky1, Jens Buentzel3, Dirk Esser4, Daniel Böger5, Andreas Müller6, Stefan Schultze-Mosgau7, Peter Schlattmann8, Harald Schmalenberg9. 1. Department of Otorhinolaryngology, Jena University Hospital, Jena, Germany. 2. Department of Radiooncology, Jena University Hospital, Jena, Germany. 3. Department of Otorhinolaryngology, Suedharzkrankenhaus Nordhausen, Nordhausen, Germany. 4. Department of Otorhinolaryngology, Helios-Klinikum Erfurt, Erfurt, Germany. 5. Department of Otorhinolaryngology, SRH Zentralklinikum Suhl, Suhl, Germany. 6. Department of Otorhinolaryngology, SRH Wald-Klinikum Gera, Gera, Germany. 7. Department of Oromaxillofacial Surgery and Plastic Surgery, Jena University Hospital, Jena, Germany. 8. Department of Medical Statistics, Computer Sciences and Documentation, Jena University Hospital, Jena, Germany. 9. University Tumor Center, Jena University Hospital, Jena, Germany.
Abstract
INTRODUCTION: The objective of this study was to examine patterns of care and survival in a population-based sample of patients with head neck cancer (HNC) who were treated in Thuringia, a federal state in Germany, between 1996 and 2011. METHODS: Data of 6291 patients with primary HNC from the Thuringian cancer registry were used to evaluate for patient's characteristics, tumor stage, incidence, and trends in treatment and overall survival (OS). RESULTS: The distribution between stages I-IV did not change significantly during the observation period. Crude incidences of HNC increased significantly between 1996 and 2011 from 13.77 to 20.39 (relative risk [RR]=1.34; 95% confidence interval [CI]=1.25-1.45). This increase was mainly driven by a significant increase of oropharynx cancer (from 3.29 to 5.85; RR=1.67; 95%CI=1.49-1.88) and cancer of the oral cavity (3.41-5.90; RR=1.5; 95%CI=1.33-1.69). The relative frequency of multimodal therapy increased (RR=1.42; 95%CI=1.3-1.55). The use of cetuximab increased (RR=473.32; 95%CI=51.57-4344.51). The 5-year and 10-year OS for the entire cohort was 49.1% and 34.1%, respectively. The multivariable analysis has proven that male gender, age ⩾60years, therapy without surgery, and TNM stage were independent significant negative risk factors for OS (all p<0.0001). CONCLUSIONS: OS did not improve during the study period. Incidence of oral cancer is significantly increasing. Although modern treatment strategies have been included in routine HNC care over the time, outcome has not improved significantly.
INTRODUCTION: The objective of this study was to examine patterns of care and survival in a population-based sample of patients with head neck cancer (HNC) who were treated in Thuringia, a federal state in Germany, between 1996 and 2011. METHODS: Data of 6291 patients with primary HNC from the Thuringian cancer registry were used to evaluate for patient's characteristics, tumor stage, incidence, and trends in treatment and overall survival (OS). RESULTS: The distribution between stages I-IV did not change significantly during the observation period. Crude incidences of HNC increased significantly between 1996 and 2011 from 13.77 to 20.39 (relative risk [RR]=1.34; 95% confidence interval [CI]=1.25-1.45). This increase was mainly driven by a significant increase of oropharynx cancer (from 3.29 to 5.85; RR=1.67; 95%CI=1.49-1.88) and cancer of the oral cavity (3.41-5.90; RR=1.5; 95%CI=1.33-1.69). The relative frequency of multimodal therapy increased (RR=1.42; 95%CI=1.3-1.55). The use of cetuximab increased (RR=473.32; 95%CI=51.57-4344.51). The 5-year and 10-year OS for the entire cohort was 49.1% and 34.1%, respectively. The multivariable analysis has proven that male gender, age ⩾60years, therapy without surgery, and TNM stage were independent significant negative risk factors for OS (all p<0.0001). CONCLUSIONS:OS did not improve during the study period. Incidence of oral cancer is significantly increasing. Although modern treatment strategies have been included in routine HNC care over the time, outcome has not improved significantly.
Authors: Orlando Guntinas-Lichius; Thomas G Wendt; Jens Buentzel; Dirk Esser; Daniel Böger; Andreas H Mueller; Jörn-Uwe Piesold; Stefan Schultze-Mosgau; Peter Schlattmann; Harald Schmalenberg Journal: J Cancer Res Clin Oncol Date: 2015-03-24 Impact factor: 4.553
Authors: Mussab Kouka; Benjamin Koehler; Jens Buentzel; Holger Kaftan; Daniel Boeger; Andreas H Mueller; Andrea Wittig; Stefan Schultze-Mosgau; Thomas Ernst; Peter Schlattmann; Orlando Guntinas-Lichius Journal: Cancers (Basel) Date: 2022-06-07 Impact factor: 6.575
Authors: Johanna Inhestern; Katrin Oertel; Viola Stemmann; Harald Schmalenberg; Andreas Dietz; Nicole Rotter; Johannes Veit; Martin Görner; Holger Sudhoff; Christian Junghanß; Claus Wittekindt; Katharina Pachmann; Orlando Guntinas-Lichius Journal: PLoS One Date: 2015-07-17 Impact factor: 3.240
Authors: Irene Göllnitz; Johanna Inhestern; Thomas G Wendt; Jens Buentzel; Dirk Esser; Daniel Böger; Andreas H Mueller; Jörn-Uwe Piesold; Stefan Schultze-Mosgau; Ekkehard Eigendorff; Peter Schlattmann; Orlando Guntinas-Lichius Journal: Cancer Med Date: 2016-10-11 Impact factor: 4.452